Effects of mesalazine combined with bifico on the treatment of ulcerative colitis and on TLR4 and MyD88
10.3760/cma.j.issn.1008-1372.2014.04.021
- VernacularTitle:美沙拉嗪联合培菲康治疗溃疡性结肠炎患者的疗效及对 TLR4、MyD88的影响
- Author:
Yongping ZHANG
;
Yifeng ZHOU
;
Pingfan WANG
;
Huyun GAO
;
Xican YU
- Publication Type:Journal Article
- Keywords:
Colitis,ulcerative/drug therapy;
Mesalamine/therapeutic use;
Probiotics/therapeutic use;
Toll-like receptor 4/blood;
Myeloid differentiation factor 88/blood
- From:
Journal of Chinese Physician
2014;(4):498-500
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy of mesalazine combined with bifico in the treatment of ulcerative co -litis (UC) and its effect on toll-like receptor 4 (TLR4) and myeloid differentiation factor 88 (MyD88).Methods A total of 86 cases of UC was randomly divided into the observation and control groups with 43 cases in each group .The observation group was given me-salazine combined bifico treatment , and the control group was given mesalazine , and eight weeks as a course of treatment .The clinical efficacy was observed .Serum TLR4 and MyD88 were tested.Adverse reaction in treatment was recorded .Results The total effective rate (95.35%) in observation group was significantly higher than that (81.40%) in control group( P <0.05).The serum TLR4 and MyD88 after treatment of two groups were significantly lower than that before treatment , respectively ( P <0.05 or P <0.01 ) , and the decline in TLR4 of observation group was superior to that of control group ( P <0.05 ) .The difference of adverse reaction rate in two groups was not significant ( P >0.05 ) .Conclusions Mesalazine combined with bifico in the treatment of UC is safe and effective . The effect may be related to regulation of peripheral blood TLR 4 and MyD88 content .
